Lai Richard Hc, Kim Deborah, Constantinescu Florina
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA.
Department of Rheumatology, Medstar Washington Hospital Center, Washington, USA; Department of Clinical Medicine, Georgetown University Medical, Center, Washington, USA.
Eur J Rheumatol. 2016 Dec;3(4):188-190. doi: 10.5152/eurjrheum.2016.15083. Epub 2016 Dec 1.
Belimumab was approved by the United States Food and Drug Administration in March 2011 as the first biological agent for treating active systemic lupus erythematosus (SLE). To the best of our knowledge, this is the first case report regarding a patient with SLE treated with belimumab who was diagnosed with central nervous system nocardiosis.
贝利尤单抗于2011年3月获美国食品药品监督管理局批准，成为首个用于治疗活动性系统性红斑狼疮（SLE）的生物制剂。据我们所知，这是首例关于使用贝利尤单抗治疗的SLE患者被诊断为中枢神经系统诺卡菌病的病例报告。
